Entering text into the input field will update the search result below

DURECT Corporation (DRRX) CEO Jim Brown on Q4 2020 Results - Earnings Call Transcript

Mar. 04, 2021 10:10 PM ETDURECT Corporation (DRRX)
SA Transcripts profile picture
SA Transcripts

DURECT Corporation (NASDAQ:DRRX) Q4 2020 Earnings Conference Call March 4, 2021 4:30 PM ET

Company Participants

Mike Arenberg - CFO

Jim Brown - President & CEO

WeiQi Lin - EVP, Research & Development & Principal Scientist

Norman Sussman - Chief Medical Officer

Conference Call Participants

Francois Brisebois - Oppenheimer

Kristen Kluska - Cantor Fitzgerald

Sahil Kazmi - B. Riley

Michael Morabito - Chardan Capital Markets

Ed Arce - H.C. Wainwright


Greetings, and welcome to the DURECT Corporation Fourth Quarter and Fiscal Year 2020 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Mike Arenberg, Chief Financial Officer. Than you, you may begin.

Mike Arenberg

Good afternoon, and welcome to our fourth quarter 2020 earnings conference call. This is Mike Arenberg, Chief Financial Officer of DURECT Corporation. I will provide a brief review of our financial results, and then Jim Brown, our President and CEO, will provide an update of our programs. We will then open up the call for a question-and-answer session.

Before beginning, I would like to remind you of our Safe Harbor Statement. During the course of this call, we may make forward-looking statements regarding DURECT's products and development, expected product benefits, our development plans, future clinical trials or projected financial results. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Further information regarding these and other risks can be found in the SEC filings, including our 10-K and 10-Qs under the heading Risk Factors.

Before I get into the financial results, it will be helpful if I explain how the sale of the LACTEL

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.